Attached To Carbohydrate Compound; Derivative Thereof (e.g., Dna, Nucleotide, Nucleoside, Sugar, Starch, Tannin, Saccharide, Polysaccharide, Cellulose, O-, N- And S-glycoside, Vitamin B12) Patents (Class 424/1.73)
-
Patent number: 8846003Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.Type: GrantFiled: March 27, 2009Date of Patent: September 30, 2014Assignee: Symic Biomedical, Inc.Inventors: Alyssa Panitch, John E. Paderi, Kinam Park, Katherine Stuart, Steve Higbee
-
Patent number: 8845999Abstract: Radiolabeled tracers for sodium/glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C 1 preferred conformation, radiolabeled with 18F, 123I, or 124I, or free hexoses radiolabeled with 18F, 123I, or 124. Also provided are in vivo and in vitro techniques for using these and other tracers as analytical and diagnostic tools to study glucose transport, in health and disease, and to evaluate therapeutic interventions.Type: GrantFiled: May 23, 2006Date of Patent: September 30, 2014Assignee: The Regents of the University of CaliforniaInventors: Ernest M. Wright, Jorge R. Barrio, Bruce A. Hirayama, Vladimir Kepe
-
Publication number: 20140271470Abstract: The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Laurel O. Sillerud, David L. Vander Jagt, Lorraine Deck
-
Publication number: 20140255307Abstract: The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Dae Ro AHN, Se Hoon KIM
-
Patent number: 8828355Abstract: Disclosed are compositions and methods for imaging in animals.Type: GrantFiled: September 16, 2005Date of Patent: September 9, 2014Assignee: University of Utah Research FoundationInventors: Charles Keller, Patrick J. Hawkes
-
Publication number: 20140248212Abstract: Embodiments of the invention include a PET/SPECT reporter gene system that uses enhanced non-immunogenic versions of a human mitochondrial thymidine kinase 2 expressed in cytoplasm to preferentially trap novel PET/SPECT radiolabeled L and D-enantiomer analogs of the natural substrate thymidine. Such highly sensitive, non-immunogenic reporter genes function in combination with a set of novel, radiolabeled probes in whole body molecular imaging applications using positron emission tomography (PET) or single photon emission computed tomography (SPECT).Type: ApplicationFiled: August 6, 2012Publication date: September 4, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Caius G. Radu, Johannes Czernin, Dean O. Campbell, Shahriar S. Yaghoubi, Nagichettiar Satyamurthy, Arnon Lavie
-
Patent number: 8822544Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: March 22, 2014Date of Patent: September 2, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Patent number: 8822545Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: May 7, 2014Date of Patent: September 2, 2014Assignee: LiveLeaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Publication number: 20140234216Abstract: The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.Type: ApplicationFiled: August 10, 2012Publication date: August 21, 2014Applicant: MERCK & CIEInventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Harriet Struthers, Viola Groehn, Simon Mensah Ametamey, Cindy Ramona Fischer
-
Publication number: 20140234217Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. Components of the targeted delivery compositions are put together through duplex formation between oligonucleotides.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventor: Thomas Edward Rogers
-
Patent number: 8809399Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: May 7, 2014Date of Patent: August 19, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Publication number: 20140227182Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.Type: ApplicationFiled: February 18, 2014Publication date: August 14, 2014Applicants: THE JOHNS HOPKINS UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITYInventors: Martin Gilbert POMPER, Hyo-eun BHANG, Paul FISHER
-
Publication number: 20140219916Abstract: This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. The illustrative embodiment produces the compound/agent containing a DNA fragment and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). The same P-32 labeled DNA can be employed directly for cancer treatment through a novel medical treatment method.Type: ApplicationFiled: February 4, 2014Publication date: August 7, 2014Inventors: Yanping Kong, Jinhong Liu
-
Publication number: 20140219917Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.Type: ApplicationFiled: February 26, 2014Publication date: August 7, 2014Applicants: Emory University, Georgia State Research Foundation, Georgia Tech Research CorporationInventors: Niren MURTHY, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
-
Publication number: 20140193337Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.Type: ApplicationFiled: August 21, 2012Publication date: July 10, 2014Applicant: MERCK & CIEInventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Simon Mensah Ametamey, Cindy Ramona Fischer, Viola Groehn
-
Patent number: 8772352Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: March 22, 2014Date of Patent: July 8, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Patent number: 8772350Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: February 5, 2014Date of Patent: July 8, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Patent number: 8772351Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: February 5, 2014Date of Patent: July 8, 2014Assignee: Liveleaf, IncInventors: Alexander L Huang, Gin Wu
-
Publication number: 20140186262Abstract: A novel gall bladder image agent which includes a radio-labelled MAG3-tri-galactosamine, and its preparation method, which includes reacting mercaptoacetyltriglycine (MAG3)-tri-galactosamine, SnF2 and Tc-99m in the presence of a phosphate buffer solution (at pH of from 10.0˜12.0) to obtain Tc-99m-MAG3-tri-galactosamine, when the MAG3-tri-galactosamine is MAG3-DCM-Lys(Gah-GalNAc)3 (where DCM represents a dicarboxymethyl group, and Gah represents a glycine-aminohexyl group), it obtains a labelling yield of at least 90%, and its specific radioactivity is at least 7.0×109 Bq/mg.Type: ApplicationFiled: December 30, 2013Publication date: July 3, 2014Applicant: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUANInventors: MEI-HUI WANG, HUNG-MAN YU, CHUAN-YI CHIEN, PING-YEN WANG, WUU-JYH LIN, KUN-LIANG LIN, JEN-TSUNG WANG
-
Patent number: 8765096Abstract: The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises a diagnostic marker, and diagnosing the kidney disease state. The invention also relates to a method for treating a kidney disease state. The method comprises the steps of administering to a patient suffering from the disease state an effective amount of a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises an antigen, a cytotoxin, or a cell growth inhibitor, and eliminating the disease state.Type: GrantFiled: April 5, 2012Date of Patent: July 1, 2014Assignee: Endocyte, IncInventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov
-
Patent number: 8765818Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: December 29, 2013Date of Patent: July 1, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Publication number: 20140178298Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: ApplicationFiled: December 9, 2013Publication date: June 26, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Publication number: 20140178303Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: December 13, 2013Publication date: June 26, 2014Applicant: GLYCOMIMETICS, INC.Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 8747810Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.Type: GrantFiled: December 13, 2011Date of Patent: June 10, 2014Assignee: President and Fellows of Harvard CollegeInventors: Ashfaq Mahmood, Alun G. Jones, Naengnoi Limpa-Amara, Yijie Peng, Zeynep Akgun
-
Patent number: 8716352Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: February 20, 2013Date of Patent: May 6, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Patent number: 8715737Abstract: The present invention relates a method to make porous materials which are useful in pharmaceutical, medicine, industry, and agriculture. The most advantage of the porous materials is to provide extremely large surface area for further modification and to incorporate a bioactive reagent in a mild condition to make the porous materials bioactive, biocompatible and biodegradable.Type: GrantFiled: January 21, 2010Date of Patent: May 6, 2014Inventor: Zhuo Joe Zhang
-
Patent number: 8716353Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: December 29, 2013Date of Patent: May 6, 2014Assignee: LiveLeaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Patent number: 8716351Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.Type: GrantFiled: December 23, 2012Date of Patent: May 6, 2014Assignee: Liveleaf, Inc.Inventors: Alexander L Huang, Gin Wu
-
Publication number: 20140099262Abstract: The present invention provides CDP-Choline (Citicoline) and any salt thereof comprising at least one isotopically labeled carbon atom directly bonded to at least one deuterium atom, a composition comprising said CDP-Choline, uses thereof, methods for diagnosing and evaluating a state, condition, or disease in a subject utilizing CDP-Choline of the invention and kits comprising CDP-Choline of the invention.Type: ApplicationFiled: May 31, 2012Publication date: April 10, 2014Applicant: BRAIN WATCH LTD.Inventors: Rachel Katz-Brull, Moshe Gomori
-
Patent number: 8691186Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: GrantFiled: August 28, 2012Date of Patent: April 8, 2014Assignee: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Patent number: 8685368Abstract: A new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications, including, a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response is provided. Complexes including a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells is also provided. The cellular delivery molecules may include one or more polymers, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters.Type: GrantFiled: July 3, 2012Date of Patent: April 1, 2014Inventor: Theresa M. Reineke
-
Patent number: 8685370Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.Type: GrantFiled: March 13, 2009Date of Patent: April 1, 2014Assignees: Visen Medical, Inc., Merck & Co., Inc.Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
-
Patent number: 8680069Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.Type: GrantFiled: May 18, 2013Date of Patent: March 25, 2014Assignee: Moderna Therapeutics, Inc.Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
-
Patent number: 8668900Abstract: The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99mTcO4, which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.Type: GrantFiled: February 15, 2011Date of Patent: March 11, 2014Assignee: Kuwait UniversityInventor: Fatma Jassab Faleh Marzooq Al-Saeedi
-
Publication number: 20140065065Abstract: An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed to 99mTc wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n (NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
-
Patent number: 8658130Abstract: Suggested are agrochemical compositions, comprising (a) biocides, and (b) alkoxylation products of di- and/or oligosaccharide esters.Type: GrantFiled: February 4, 2010Date of Patent: February 25, 2014Assignee: Cognis IP Management GmbHInventors: Hans-Georg Mainx, Peter Hofer
-
Publication number: 20140044642Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.Type: ApplicationFiled: October 14, 2013Publication date: February 13, 2014Applicant: Avid Radiopharmaceuticals, Inc.Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter
-
Patent number: 8642007Abstract: This invention provides a combination of a gene and isotope therapy that is applied to a cancerous tissue to selectively kill that associated cancer cells with minimal negative effects on surrounding non-cancerous cells. Functionally, the specific DNA fragments with labeled isotope are able to bind the tumor cells DNA through recombination, and then the isotope kills the tumor cells. A gene is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Unlike traditional gene therapy, which employs a gene to express a protein, which can suppress the cancer cell growth or increase the sensitivity for radiation therapy or chemotherapy, the illustrative embodiment actually binds the radioactive substance via a gene.Type: GrantFiled: September 20, 2010Date of Patent: February 4, 2014Inventors: Yanping Kong, Jinhong Liu
-
Publication number: 20140023586Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: Navidea Biopharmaceuticals, Inc.Inventors: Gerald Ross Magneson, Richard Cushman Orahood
-
Patent number: 8632991Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.Type: GrantFiled: January 13, 2011Date of Patent: January 21, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
-
Patent number: 8623328Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: August 9, 2012Date of Patent: January 7, 2014Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Patent number: 8603436Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.Type: GrantFiled: March 11, 2011Date of Patent: December 10, 2013Inventor: Gerhart Graupner
-
Patent number: 8603437Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: GrantFiled: April 30, 2012Date of Patent: December 10, 2013Assignee: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Patent number: 8574546Abstract: Substituted aryl-boron compounds comprising at least one 18F atom, as illustrated by the formula (I), where at least one of Y1 or Y2 is 18F and A1 is a substituted aromatic ring, with G1-5 being, independently, C or N, and where the substitutents of the aromatic ring or polycyclic moiety (other than boron) comprise at least one electron-withdrawing group (EWG), providing that sigma total (?total) for all substituents on the aromatic ring or polycyclic moiety except B is about 0.06 or more when said at least one EWG is positioned ortho to B, or about 0.2 or more when no EWG is positioned ortho to B. The compounds include neutral (N=1) and ionic borate (N=2) embodiments. The compounds are useful as positron emission tomography (PET) imaging agents.Type: GrantFiled: July 24, 2008Date of Patent: November 5, 2013Assignee: The University of British ColumbiaInventors: David Perrin, Richard Ting, Christopher Overall
-
Patent number: 8574544Abstract: The invention discloses a pharmaceutical composition of nanoparticles consisting of chitosan, a negatively charged substrate, and at least one bioactive agent that is encapsulated within cucurbiturils for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: December 21, 2012Date of Patent: November 5, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Ha Giang Thi Nguyen, Fang Yi Su, Er-Yuan Chuang, Zi-Xian Liao, Hosheng Tu
-
Publication number: 20130289385Abstract: Methods and apparatus for screening patients prior to deep brain stimulation to treat cognitive function are provided. One or more patient parameters are processed to produce results. A comparison of the results to a threshold indicates the applicability of the deep brain stimulation therapy.Type: ApplicationFiled: October 19, 2012Publication date: October 31, 2013Applicant: Functional Neuromodulation, Inc.Inventors: Andres Lozano, J. Christopher Flaherty
-
Patent number: 8557222Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.Type: GrantFiled: April 3, 2009Date of Patent: October 15, 2013Assignee: Avid Radiopharmaceuticals, Inc.Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter, Jr.
-
Patent number: 8551453Abstract: The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.Type: GrantFiled: December 29, 2004Date of Patent: October 8, 2013Assignee: The Regents of the University of CaliforniaInventors: Kenneth N. Raymond, Stephane Petoud, Jide Xu
-
Patent number: 8551447Abstract: A bifunctional compound with a monosaccharide and a N2S2 ligand, and more particularly, a bifunctional compound with a N2S2 ligand and aminohexylacetyl galactosamine (ah-GalNAc4) is provided. A method for preparing the bifunctional compound with a monosaccharide and a N2S2 ligand is also provided, including activating a carboxyl group in an organic ligand, reacting the activated carboxyl group with a galactopyranoside through amidation, and then hydrolyzing. The bifunctional compound of the present invention is widely useful in nuclear medicine for preparation of liver imaging agents for assisting in correct diagnosis of diseases.Type: GrantFiled: April 15, 2011Date of Patent: October 8, 2013Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Show-Wen Liu, Cheng-Hsien Lin, Yu Chang, Cheng-Fang Hsu, Tsyh-Lang Lin
-
Publication number: 20130263296Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.Type: ApplicationFiled: October 28, 2011Publication date: October 3, 2013Applicants: THE JOHNS HOPKINS UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITYInventors: Martin Gilbert Pomper, Hyo-eun Bhang, Paul Fisher